These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 38196538)

  • 1. Efficacy and safety of regorafenib as second-line treatment for patients with hepatocellular carcinoma and macrovascular invasion and(or) extrahepatic metastasis.
    Zhao Y; Liu W; Zheng L; Goyal S; Awosika J; Wang H; Yang S
    J Gastrointest Oncol; 2023 Dec; 14(6):2536-2548. PubMed ID: 38196538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice.
    Liu K; Wu J; Xu Y; Li D; Huang S; Mao Y
    Onco Targets Ther; 2022; 15():1079-1094. PubMed ID: 36212725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a two-center study in China.
    Ren SH; Cui ZL; Lang MR; Li Q; Zhang W; Fang F; Wu Q; Cui YL; Li HK; Chen P; Zhang Y; Song T
    J Gastrointest Oncol; 2022 Jun; 13(3):1266-1277. PubMed ID: 35837206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-center retrospective study on the efficacy and safety of regorafenib
    Yan T; Huang C; Peng C; Duan X; Ji D; Duan Y; Zhang W; Zhao H; Gao K; Yang X; Zhang L; Cheng J; de Castria TB; Pocha C; Tsilimigras DI; Wu T; Su G; Li Y; Yu L; Lu Y
    Ann Transl Med; 2023 Jan; 11(2):109. PubMed ID: 36819518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study on safety and efficacy of regorafenib combined with transcatheter arterial chemoembolization in the treatment of advanced hepatocellular carcinoma after first-line targeted therapy.
    Wang H; Xiao W; Han Y; Cao S; Zhang Z; Chen G; Hu Y; Jin L
    J Gastrointest Oncol; 2022 Jun; 13(3):1248-1254. PubMed ID: 35837179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study.
    Yu J; Bai Y; Cui Z; Cheng C; Ladekarl M; Cheng KC; Chan KS; Yarmohammadi H; Mauriz JL; Zhang Y
    J Gastrointest Oncol; 2024 Jun; 15(3):1072-1081. PubMed ID: 38989425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of regorafenib in combination with immune checkpoint inhibitor therapy as second-line and third-line regimen for patients with advanced hepatocellular carcinoma: a retrospective study.
    Zhao J; Guo Y; Feng T; Rong D; Kong X; Huang T; Lopez-Lopez V; Yarmohammadi H; Sakamoto Y; Zhu D; Yao A; Xia Y
    J Gastrointest Oncol; 2023 Dec; 14(6):2549-2558. PubMed ID: 38196523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
    Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
    Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
    Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
    Chen J; Wang J; Xie F
    Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy.
    Xu B; Lu D; Liu K; Lv W; Xiao J; Zhang X; Zhang Z; Chai J; Wang L
    Drug Des Devel Ther; 2023; 17():507-518. PubMed ID: 36814894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma.
    Wang HW; Chuang PH; Su WP; Kao JT; Hsu WF; Lin CC; Huang GT; Lin JT; Lai HC; Peng CY
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A new prognostic score system of hepatocellular carcinoma following hepatectomy].
    Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ
    Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506
    [No Abstract]   [Full Text] [Related]  

  • 15. Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study.
    Kim BH; Park HC; Kim TH; Koh YH; Hong JY; Cho Y; Sinn DH; Park B; Park JW
    JHEP Rep; 2024 Apr; 6(4):100991. PubMed ID: 38463541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study.
    Zhai J; Liu J; Fu Z; Bai S; Li X; Qu Z; Sun Y; Ge R; Xue F
    J Gastrointest Oncol; 2022 Jun; 13(3):1278-1288. PubMed ID: 35837155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.
    Iavarone M; Invernizzi F; Czauderna C; Sanduzzi-Zamparelli M; Bhoori S; Amaddeo G; Manini MA; López MF; Anders M; Pinter M; Rodríguez MJB; Cristóbal MR; Soteras GA; Piñero F; Villadsen GE; Weinmann A; Crespo G; Mazzaferro V; Regnault H; Giorgio M; González-Diéguez ML; Donato MF; Varela M; Wörns MA; Bruix J; Lampertico P; Reig M
    Am J Transplant; 2019 Nov; 19(11):3176-3184. PubMed ID: 31365177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-Life Experience of Regorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Hou JY; Xiao YT; Huang JB; Jiang XH; Jiang K; Li X; Xu L; Chen MS
    Front Pharmacol; 2022; 13():917384. PubMed ID: 35734398
    [No Abstract]   [Full Text] [Related]  

  • 19. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels.
    Hsu PY; Cheng TS; Chuang SC; Chang WT; Liang PC; Hsu CT; Wei YJ; Jang TY; Yeh ML; Huang CI; Lin YH; Wang CW; Hsieh MY; Hou NJ; Hsieh MH; Tsai YS; Ko YM; Lin CC; Chen KY; Dai CY; Lin ZY; Chen SC; Huang JF; Chuang WL; Huang CF; Yu ML
    Cancer Med; 2022 Jan; 11(1):104-116. PubMed ID: 34786871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of fruquintinib and regorafenib in the treatment of metastatic colorectal cancer: A real-world study.
    Deng YY; Zhang XY; Zhu PF; Lu HR; Liu Q; Pan SY; Chen ZL; Yang L
    Front Oncol; 2023; 13():1097911. PubMed ID: 36937443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.